JP2010513551A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513551A5 JP2010513551A5 JP2009543060A JP2009543060A JP2010513551A5 JP 2010513551 A5 JP2010513551 A5 JP 2010513551A5 JP 2009543060 A JP2009543060 A JP 2009543060A JP 2009543060 A JP2009543060 A JP 2009543060A JP 2010513551 A5 JP2010513551 A5 JP 2010513551A5
- Authority
- JP
- Japan
- Prior art keywords
- prostaglandin
- amide
- ether
- ester
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 24
- 150000001408 amides Chemical class 0.000 claims 13
- 150000003180 prostaglandins Chemical class 0.000 claims 13
- 239000000556 agonist Substances 0.000 claims 12
- 229940002612 prodrug Drugs 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- -1 glucoside esters Chemical class 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 150000002148 esters Chemical class 0.000 claims 6
- 208000007882 Gastritis Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 206010059024 Gastrointestinal toxicity Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 231100000414 gastrointestinal toxicity Toxicity 0.000 claims 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 3
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- 206010022714 Intestinal ulcer Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 208000000718 duodenal ulcer Diseases 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 229930182478 glucoside Natural products 0.000 claims 2
- 229930182480 glucuronide Natural products 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 208000012895 Gastric disease Diseases 0.000 claims 1
- 208000036495 Gastritis atrophic Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 1
- 208000023652 chronic gastritis Diseases 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960000616 diflunisal Drugs 0.000 claims 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 206010013864 duodenitis Diseases 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 229960005293 etodolac Drugs 0.000 claims 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 1
- 229960001419 fenoprofen Drugs 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000000052 gastrinoma Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 229940037467 helicobacter pylori Drugs 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960003464 mefenamic acid Drugs 0.000 claims 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 1
- 229960001929 meloxicam Drugs 0.000 claims 1
- 229960004270 nabumetone Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 229960000894 sulindac Drugs 0.000 claims 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960001017 tolmetin Drugs 0.000 claims 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Claims (15)
- 前記疾患または症状が、ヘリコバクター・ピロリ(Heliobacter pylori)誘発性胃炎、萎縮性胃炎、悪性貧血、ストレス性粘膜障害、アルコール性胃疾患、胃潰瘍、十二指腸潰瘍、腸潰瘍、術後アルカリ性胃炎および好酸球性胃腸炎からなる群から選ばれる胃炎である、請求項1記載の使用。
- 前記哺乳類が、前記症状または疾患に対して予防的治療を必要とする、請求項1または2記載の使用。
- 前記疾患または症状の治療または予防が、前記プロスタグランジンEP4アゴニスト成分を、哺乳類の胃腸管に投与することを含む、請求項1〜3のいずれか一項に記載の使用。
- 前記プロスタグランジンEP4レセプターアゴニスト成分が、前記プロスタグランジンEP4アゴニスト、前記プロスタグランジンEP4アゴニストの製薬上許容し得る塩、前記プロスタグランジンEP4アゴニストのプロドラッグ、またはこれら薬剤の2種以上の混合物を含む、請求項1〜4のいずれか一項に記載の使用。
- 前記プロスタグランジンEP4アゴニスト成分が、プロスタグランジンEP4アゴニストのプロドラッグを含む、請求項1〜5のいずれか一項に記載の使用。
- 前記プロドラッグが、炭水化物のエステル、エーテルまたはアミドであるか;或いは、前記プロドラッグが、アミノ酸のエステル、エーテルまたはアミドである、請求項6記載の使用。
- 前記プロドラッグが、アミノ酸のアミド、エステルまたはエーテルである、請求項6記載の使用。
- 前記プロスタグランジンEP4アゴニスト成分が、グルコシドエステル、エーテルまたはアミド;グルクロニドエステル、エーテルまたはアミド;シクロデキストリンエステル、エーテルまたはアミド;或いは、デキストランエステル、エーテルまたはアミドを含む、請求項6記載の使用。
- 前記プロスタグランジンEP4アゴニスト成分が、プロスタグランジンEP4アゴニストのプロドラッグを含む、請求項10記載の組成物。
- 前記プロドラッグが、炭水化物のエステル、エーテルまたはアミドであるか;或いは、前記プロドラッグが、アミノ酸のエステル、エーテルまたはアミドである、請求項11記載の組成物。
- 前記プロドラッグが、アミノ酸のアミド、エステルまたはエーテルである、請求項11記載の組成物。
- 前記プロスタグランジンEP4アゴニスト成分が、グルコシドエステル、エーテルまたはアミド;グルクロニドエステル、エーテルまたはアミド;シクロデキストリンエステル、エーテルまたはアミド;或いは、デキストランエステル、エーテルまたはアミドを含む、請求項11記載の組成物。
- 前記NSAIDを、アスピリン、アセトメニフェン(acetomenifen)、インドメタシン、イブプロフェン、ケトロラック、ナポキセン(napoxen)、ピロキシカム、ナブメトン、セレコキシブ、ジクロフェナク、ジフルニサル、エトドラク、フェノプロフェン、ケトプロフェン、メフェナム酸、メロキシカム、ナブメトン、オキサプロジン、スリンダクおよびトルメチンからなる群から選択する、請求項10記載の組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87044406P | 2006-12-18 | 2006-12-18 | |
PCT/US2007/087042 WO2008076703A1 (en) | 2006-12-18 | 2007-12-11 | Methods and compositions for treating gastrointestinal disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014168689A Division JP2014210824A (ja) | 2006-12-18 | 2014-08-21 | 胃腸疾患の治療方法および組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010513551A JP2010513551A (ja) | 2010-04-30 |
JP2010513551A5 true JP2010513551A5 (ja) | 2011-02-03 |
Family
ID=39059771
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009543060A Ceased JP2010513551A (ja) | 2006-12-18 | 2007-12-11 | 胃腸疾患の治療方法および組成物 |
JP2014168689A Ceased JP2014210824A (ja) | 2006-12-18 | 2014-08-21 | 胃腸疾患の治療方法および組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014168689A Ceased JP2014210824A (ja) | 2006-12-18 | 2014-08-21 | 胃腸疾患の治療方法および組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100081631A1 (ja) |
EP (3) | EP2548559A1 (ja) |
JP (2) | JP2010513551A (ja) |
AU (1) | AU2007334038A1 (ja) |
BR (1) | BRPI0721067A2 (ja) |
CA (1) | CA2690273A1 (ja) |
WO (1) | WO2008076703A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7855226B2 (en) * | 2003-02-11 | 2010-12-21 | Allergan, Inc. | Treatment of inflammatory bowel disease |
KR20150050595A (ko) | 2006-03-28 | 2015-05-08 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
US20090012165A1 (en) * | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
AU2011282549A1 (en) * | 2010-07-30 | 2013-02-28 | Allergan, Inc. | Compounds and methods for skin repair |
US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
RU2586040C1 (ru) * | 2014-12-25 | 2016-06-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия" Министерства Здравоохранения Российской Федерации (ГБОУ ВПО НижГМА Минздрава России) | Способ диагностики идиопатической язвенной болезни желудка и двенадцатиперстной кишки |
CN107849072B (zh) | 2015-06-12 | 2020-12-15 | 西蒙弗雷泽大学 | 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途 |
NL2018407B1 (en) * | 2017-02-22 | 2018-09-17 | Skytree B V | Improved process and apparatus for the removal of metabolic carbon dioxide from a confined space |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL110298A (en) | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
US6586468B1 (en) | 1998-09-14 | 2003-07-01 | Ono Pharmaceutical Co., Ltd. | ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient |
CN1476429A (zh) * | 2000-11-27 | 2004-02-18 | �Ʒ� | 治疗骨质疏松的ep4受体选择性激动剂 |
WO2003074483A1 (fr) * | 2002-03-05 | 2003-09-12 | Ono Pharmaceutical Co., Ltd. | Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif |
US7855226B2 (en) * | 2003-02-11 | 2010-12-21 | Allergan, Inc. | Treatment of inflammatory bowel disease |
CA2585367A1 (en) * | 2004-10-26 | 2006-05-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
US7893107B2 (en) * | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
-
2007
- 2007-12-11 CA CA2690273A patent/CA2690273A1/en not_active Abandoned
- 2007-12-11 EP EP12188643A patent/EP2548559A1/en not_active Withdrawn
- 2007-12-11 BR BRPI0721067-1A patent/BRPI0721067A2/pt not_active IP Right Cessation
- 2007-12-11 WO PCT/US2007/087042 patent/WO2008076703A1/en active Application Filing
- 2007-12-11 EP EP07855057A patent/EP2120962A1/en not_active Ceased
- 2007-12-11 JP JP2009543060A patent/JP2010513551A/ja not_active Ceased
- 2007-12-11 US US12/519,215 patent/US20100081631A1/en not_active Abandoned
- 2007-12-11 EP EP12159850A patent/EP2465506A1/en not_active Withdrawn
- 2007-12-11 AU AU2007334038A patent/AU2007334038A1/en not_active Abandoned
-
2014
- 2014-08-21 JP JP2014168689A patent/JP2014210824A/ja not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010513551A5 (ja) | ||
WO2009017716A3 (en) | Pulsatile gastric retentive dosage forms | |
WO2011079239A3 (en) | Combination tablet with chewable outer layer | |
ES2611483T3 (es) | Agente terapéutico para enfermedad inflamatoria intestinal | |
NO20084296L (no) | Pharmasoytisk kombinasjon omfattende 3- (3-dimetylamin0-1-etyl-2-metyl-propyl)-fenol og et nsaid | |
JP2001515033A5 (ja) | ||
MA29860B1 (fr) | Modulateurs du metabolisme et le traitement de troubles s'y rapportant | |
WO2009092073A3 (en) | Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects | |
NO20092398L (no) | Krystallinske former av solvatisert ilaprazol | |
JP2006518751A5 (ja) | ||
JP2011500595A5 (ja) | ||
JP2014210824A5 (ja) | ||
EA201100857A1 (ru) | Фармацевтическая композиция ингибитора протонной помпы и пребиотика для лечения язвенных поражений желудка и 12-перстной кишки | |
EP1962868A4 (en) | COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING POST-OPERATIVE ILEUS AND GASTRIC STAIN | |
JP2011157375A5 (ja) | ||
HK1155663A1 (en) | Combination therapy of lower urinary tract disorders with | |
ES2511792T3 (es) | Composiciones y métodos para la inhibición de la secreción de ácido gástrico usando derivados de pequeños ácidos dicarboxílicos en combinación con IBP | |
KR20090051273A (ko) | 세포 손상 및 염증 질환의 치료 또는 예방용 약학 조성물 | |
BRPI0713338A2 (pt) | formulaÇÕes galÊnicas de compostos orgÂnicos | |
WO2008011016A3 (en) | Treating gastroesophageal reflux disease with 5-ht3- and gaba receptor agonists | |
RU2007116969A (ru) | Средство для профилактики или лечения метаболического синдрома | |
US8747920B2 (en) | Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic-analgesic drug and proton pump inhibitor | |
RU2015106931A (ru) | Лекарственное средство от гастроэзофагеальной рефлюксной болезни | |
JP2006516279A5 (ja) | ||
ES2306905T3 (es) | Utilizacion del tenatoprazol para el tratamiento del reflujo gastroesofagico. |